Safety and Immunogenicity of Standard and Double Doses of Hepatitis B Vaccine in Children after Liver Transplantation: An Open-Label, Randomised Controlled Trial
Authors:
- Palittiya SintusekPalittiya Sintusek
- Supranee BuranapraditkunSBSupranee Buranapraditkun
- Piyaporn WanawongsawadPWPiyaporn Wanawongsawad
- Nawarat PosuwanNPNawarat Posuwan
- Pattarawat ThantiworasitPTPattarawat Thantiworasit
- Nasamon WanlapakornNWNasamon Wanlapakorn
- Jettanong KlaewsongkramJKJettanong Klaewsongkram
- Narissara SuratannonNSNarissara Suratannon
- Nataruks ChaijitraruchNCNataruks Chaijitraruch
- Voranush ChongsrisawatVCVoranush Chongsrisawat
- Yong PoovorawanYPYong Poovorawan
Open Access
Abstract
A high prevalence of hepatitis B (HepB) antibody loss after liver transplantation (LT) and de novo HepB infection (DNH) was documented, hence revaccination to prevent DNH is crucial. This study aimed to compare the safety and immunogenicity of two HepB vaccine regimens in liver-transplanted children. Liver-transplanted children who were previously immunised but showed HepB surface antibodies (anti-HBs) ≤ 100 mIU/mL were randomised to receive a standard three-dose (SD) and double three-dose (DD) vaccine intramuscularly in months 0–1–6. Anti-HBs and T-cell-specific response to the HepB antigen were assessed. A total of 61 children (54.1% male, aged 1.32 ± 1.02 years) completed the study without any serious adverse reaction. The seroprotective rate was 69.6% vs. 60% (p = 0.368) and 91.3% vs. 85% (p = 0.431) in SD and DD after the first and third 3-dose vaccinations, respectively. The geometric mean titre (95% confidence interval) of anti-HBs in SD and DD were 443.33 (200.75–979.07) vs. 446.17 (155.58–1279.50) mIU/mL, respectively, at completion. Numbers of interferon-γ-secreting cells were higher in hyporesponders/responders than in nonresponders (p = 0.003). The significant factors for the immunologic response to HepB vaccination were anti-HB levels prevaccination, tacrolimus trough levels, and time from LT to revaccination. SD and DD had comparative immunogenicity and were safe for liver-transplanted children who were previously immunised.Keywords
This publication has 31 references indexed in Scilit:
- Hepatitis B vaccination: A completed schedule enough to control HBV lifelong?Vaccine, 2013
- Hepatitis B specific T cell immunity induced by primary vaccination persists independently of the protective serum antibody levelVaccine, 2013
- Efficacy of Double-Dose Hepatitis B Rescue Vaccination in HIV-Infected PatientsAIDS Patient Care and STDs, 2010
- Serologic response to hepatitis B vaccine with high dose and increasing number of injections in HIV infected adult patientsVaccine, 2009
- Response to Booster Hepatitis B Vaccines in Liver-Transplanted Children Primarily Vaccinated in InfancyTransplantation, 2008
- A Prospective Open Study of the Efficacy of High‐Dose Recombinant Hepatitis B Rechallenge Vaccination in HIV‐Infected PatientsThe Journal of Infectious Diseases, 2008
- Vaccination Against Hepatitis B in Liver Transplant RecipientsLiver Transplantation, 2007
- Active Immunization to Prevent De Novo Hepatitis B Virus Infection in Pediatric Live Donor Liver RecipientsAmerican Journal of Transplantation, 2007
- Transcriptional control of B cell development and functionGene, 2004
- "Occult" hepatitis B virus as source of infection in liver transplant recipientsThe Lancet, 1994